88 related articles for article (PubMed ID: 24901159)
1. Assessment of angiogenesis of hepatocellular carcinoma using dynamic contrast enhanced MR and histopathologic correlation in an experimental rat model.
Lee JH; Park MJ; Kim JK; Kim YC; Kim TH; Park MS; Yu JS; Kim KW; Kim YB; Kim SH; Shim W; Kim D; Yun CO; Ahn SH
Hepatogastroenterology; 2014; 61(130):447-52. PubMed ID: 24901159
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.
Zhang W; Chen HJ; Wang ZJ; Huang W; Zhang LJ
Eur Radiol; 2017 May; 27(5):2086-2094. PubMed ID: 27488851
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
4. Perfusion-weighted MRI in evaluating the intranodular hemodynamic characteristics of dysplastic nodules and hepatocellular carcinomas in an experimental rat model.
Xu H; Xie JX; Li X; Yang ZH; Zheng ZZ; Wang B; Wang Z
J Magn Reson Imaging; 2008 Jan; 27(1):102-9. PubMed ID: 18022847
[TBL] [Abstract][Full Text] [Related]
5. Detection and characterization of hepatocellular carcinoma in rats with liver cirrhosis: diagnostic value of combined use of MR positive and negative contrast agents.
Guo DM; Qiu TS; Bian J; Liu SF; Wang CZ
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):65-70. PubMed ID: 19208518
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings.
Ishigami K; Yoshimitsu K; Nishihara Y; Irie H; Asayama Y; Tajima T; Nishie A; Hirakawa M; Ushijima Y; Okamoto D; Taketomi A; Honda H
Radiology; 2009 Feb; 250(2):435-43. PubMed ID: 19095782
[TBL] [Abstract][Full Text] [Related]
7. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
8. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
9. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced ultrasound (DCE-US) for easy and rapid evaluation of hepatocellular carcinoma compared to dynamic contrast-enhanced computed tomography (DCE-CT)--a pilot study.
Egger C; Goertz RS; Strobel D; Lell M; Neurath MF; Knieling F; Scharf M
Ultraschall Med; 2012 Dec; 33(6):587-92. PubMed ID: 23154871
[TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers.
Bartolozzi C; Battaglia V; Bargellini I; Bozzi E; Campani D; Pollina LE; Filipponi F
Abdom Imaging; 2013 Apr; 38(2):290-6. PubMed ID: 23053453
[TBL] [Abstract][Full Text] [Related]
12. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
Kim JE; Kim SH; Lee SJ; Rhim H
AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
[TBL] [Abstract][Full Text] [Related]
13. Enhancement pattern analysis of hypervascular hepatocellular carcinoma on dynamic MR imaging with histopathological correlation: validity of portal phase imaging for predicting tumor grade.
Okamoto D; Yoshimitsu K; Nishie A; Tajima T; Asayama Y; Ishigami K; Hirakawa M; Ushijima Y; Kakihara D; Nakayama T; Nishihara Y; Aishima S; Taketomi A; Kishimoto J; Honda H
Eur J Radiol; 2012 Jun; 81(6):1116-21. PubMed ID: 21420813
[TBL] [Abstract][Full Text] [Related]
14. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of noninvasive diagnostic criteria for hepatocellular carcinoma on pretransplant MRI (2010): correlation between MR imaging features and histological features on liver specimen].
Ouedraogo W; Tran-Van Nhieu J; Baranes L; Lin SJ; Decaens T; Laurent A; Djabbari M; Pigneur F; Duvoux C; Kobeiter H; Deux JF; Rahmouni A; Luciani A
J Radiol; 2011; 92(7-8):688-700. PubMed ID: 21819911
[TBL] [Abstract][Full Text] [Related]
16. Free-breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping.
Braren R; Curcic J; Remmele S; Altomonte J; Ebert O; Rummeny EJ; Steingoetter A
Invest Radiol; 2011 Oct; 46(10):624-31. PubMed ID: 21577121
[TBL] [Abstract][Full Text] [Related]
17. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular nodules in liver cirrhosis: MR evaluation.
Lee JM; Choi BI
Abdom Imaging; 2011 Jun; 36(3):282-9. PubMed ID: 21399975
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
Wang J; Chen LT; Tsang YM; Liu TW; Shih TT
AJR Am J Roentgenol; 2004 Sep; 183(3):713-9. PubMed ID: 15333360
[TBL] [Abstract][Full Text] [Related]
20. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
